NasdaqGM:WVEPharmaceuticals
Does Wave Life Sciences’ (WVE) RNA Obesity Program Signal a Shift in Its Competitive Positioning?
Wave Life Sciences recently initiated the Phase 2a multidose portion of its INLIGHT trial, testing investigational RNA therapy WVE-007 as a monotherapy for individuals with obesity, higher BMI, and cardiometabolic conditions such as type 2 diabetes.
The move follows earlier Phase 1 results showing fat loss with muscle preservation and sets up additional Phase 2 studies in 2026 combining WVE-007 with incretins and as a post-incretin maintenance approach, potentially positioning the program...